Watch VBIO Today for something Amazing!

Get VBIO on your screen for Today! VBIO could move fast so watch it! Greetings Traders, The report on VBIO is out, get this one up on your radar and do not miss out on some insane multi-digit potential! As mentioned earlier, the price on pharmaceutical related cannabis products could be showing a squeeze on supply given news of recent fires in California that have decimated growing farms right [during harvest season](. Even an unchanged demand with current affairs like that could send VBIO into new levels. But what really could be attracting a spike in volume is VBIO’s publication of their patent on their innovative product. VBIO could be adding an entirely new way of distributing medical cannabis into the system and destroying misconceptions of what the plant could be used for! Looking back, this could be the big pharmaceutical leap that could lead to greater adoption among all the other states. The Company's prodrug technology enables large concentrations of cannabinoids to be selectively delivered to the intestinal tract and avoids psychoactivity, making them well suited for treatment of pediatric conditions. Independent clinical trial results suggest that cannabinoids will help induce remission in Crohn’s disease patients, and that the vast majority of inflammatory bowel disease (“IBD”) patients experience symptomatic relief, including 84% of patients who report improvement in visceral or abdominal pain. [Approximately]( 1.4 million Americans have IBD, including Crohn’s disease and ulcerative colitis. Most patients are diagnosed before age 30 and require life-long treatment. A prodrug is a medication or compound that, after administration, is metabolized (i.e., converted within the body) into a pharmacologically active drug. The Global Advanced Drug Delivery Market is [poised]( to grow at a CAGR of around 7.8% over the next decade to reach approximately $330.70 billion by 2025. Prodrugs are typically designed to overcome well-known drawbacks of currently available therapies. Vitality’s prodrug technology enables the selective targeting of specific tissues or organs, including the gut or brain, enabling the drug to have a more targeted effect. As of 2015, there were approximately 15 prodrugs that had been classified as blockbusters, defined as having annual sales in excess of $1 billion. Only a couple days ago, VBIO [announced]( the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals. On top of that - SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today [announced]( that it has issued a company update on Vitality Biopharma, Inc. and increased its 12-month price target to $2.40 which is currently at the time of reporting a little over $1.50! Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Currently, high concentrations of psychoactive THC in the brain limit the dose of cannabinoids that can be used elsewhere in the body for treatment of pain and inflammation. They say some of the greatest achievements in Science are discovered by accident and what VBIO is coming up with seems to fall right into that! Vitality Biopharma, Inc. or VBIO focuses on the development of cannabinoid pharmaceuticals for the treatment of neurological and inflammatory disorders in the United States. Its products in pipeline include VITA-100, an oral cannabinoid formulation that is used for the acute treatment of inflammatory bowel disease and narcotic bowel syndrome; and VITA-210, a cannabinoid formulation, which is in preclinical studies for use in the chronic treatment of neuropathic pain, irritable bowel syndrome, muscle spasticity in multiple sclerosis, and opioid-induced bowel dysfunction. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. Vitality Biopharma, Inc. was founded in 2007 and is based in Los Angeles, California. Website: [( For more information, visit: [www.vitality.bio](. Social media links on [Facebook](, [Twitter]( and [LinkedIn](. VBIO’s intellectual property seems to be leading in the direction of CBD and THC dispensing. According to Forbes, [the Hemp Business Journal]( estimated that the CBD market will grow to a USD2.1 bn market in consumer sales by 2020 with USD450 Mn of those sales coming from hemp-based sources. That's a 700% increase from 2016! The average cannabis user is interested in what CBD has to offer. The largest cultivator in Southern California known as Outco [found]( that 38% of users and none users are interested in learning more about CBD oil and what it has to offer. One analytical [report]( even suggested that the molecules found in marijuana are the most disruptive molecule of today, and suggested, “a 23x market expansion, by dollar value, over 14 years, with similar growth in the consumer pool as well.” The report, further continued to suggest that, “the early stages of R&D development in pharmaceuticals of cannabis and marijuana it could be the single strongest force since modern antibiotics.” Small molecule glycosylation is well known within the pharmaceutical industry to modify and in many ways improve drug properties for cannabinoids and many other compounds, but traditionally the chemical synthesis of glycosides has been very challenging. Over the past several years, Vitality has developed efficient methods for biosynthetic production of glycosides, rather than chemical synthesis, and is now reporting a marked improvement to these biosynthetic production methods. VBIO was able to recently improve the yields of its primary enzymatic biocatalyst more than 15-fold, and over the course of the past year to reduce more than half the amount of time necessary for its production in large fermentation batches. This enzyme is a key component of Vitality's proprietary biosynthesis methods and it was originally derived from the Stevia plant. In late 2015, the Company discovered that that the enzyme was far more promiscuous and more broadly useful than researchers within the stevia industry had ever appreciated before. This discovery led to an international patent filing covering a new class of cannabinoid pharmaceutical prodrugs: [(. "With our cannabinoid pharmaceutical program, we are quickly moving from 'bench to bedside,' so it's important to recognize technical milestones like this one that have enabled and sped our progress," said Robert Brooke, CEO of Vitality Biopharma. "Our team first pioneered enzymatic biosynthesis methods for cannabosides and now has made their production far more efficient and scalable." Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits while reducing or avoiding the systemic delivery of THC into the bloodstream. The publication of the international patent filing is the first public disclosure of its full content, which includes 79 patent claims and almost 200 individual compounds. Novel cannabinoid prodrugs are described for the most common phytocannabinoids, THC, cannabidiol (CBD), and CBDV, as well as a variety of other phytocannabinoids and endocannabinoids. The Patent Cooperation Treaty (PCT) is an international patent law treaty that includes 151 countries and covers all major pharmaceutical markets worldwide. Coverage of any underlying patent claims would extend to 2035 in the United States, and may be subject to patent term extensions that would extend this patent protection. The full text may be accessed online: "[(". Additionally, the Company has filed for intellectual property coverage for methods to treat dysbiosis, gastrointestinal infections, and other digestive disorders using cannabinoids. "The publication of our international PCT patent filing gives shareholders a way to appreciate the depth and rigor of our work on the development of cannabosides," said Robert Brooke, CEO of Vitality Biopharma. "Intellectual property is at the core of nearly every successful biotechnology or drug development company, so we plan to prosecute these claims and to maximize our coverage both in the U.S. and abroad." VBIO’s products are groundbreaking in a sense though, this is one of the earliest stages where CBD and THC products are leapfrogging into another segment, biopharmaceuticals rather than simple products ingested or inhaled. Make sure you are ready to get all my alerts FAST by texting the word "ProTrader" to "99000" (regular text messaging rates may apply) Also PLEASE take the time to read the following AGAIN: ( I DO NOT MAKE ANY RECOMMENDATIONS TO BUY OR SELL ANY STOCKS, I JUST PROFILE COMPANIES AND YOU DECIDE WHAT TO DO) Placing a Trade First and foremost, you should always have streaming Level II quotes when trading. I honestly do not know how anyone trades without it! When trading, please follow the below guidelines: Always use a Limit Order: Most brokers won’t even allow you to use Market Orders. Limit Orders allow you to set the price that you want to buy and sell the stock at. This is common knowledge however, you may see some novice traders make the mistake of placing a market order to sell and take out all buyers at the bid, effectively overselling the stock to lower prices. Buy and Sell at the Ask: Many don’t realize that when you buy at the Ask price, you are HELPING the stock price to move up! Once that offer is gone from the shares you purchased, Market Makers could move up to the next offer price as they will see there are buyers at the current price. If you decide to place an order at the bid, you are basically hoping someone will sell their shares to you at this price and you may never get filled and miss the action. It is not always a bad idea to bid sit, as you are creating “bid support”, if you believe the price may come down again and you are not willing to buy higher. Using Stop Limit Orders: Some brokers do not allow you to use stops, however, if you can – it is always a good idea to set your stop loss at the lowest price you are willing to take a loss. You may kick yourself when the stock moves back up and your stop already executed, but remember, there will always be other opportunities and its always best to cut your losses just in case. All or None Orders (Fill or Kill): An example of an all or none order is when someone places an order to buy 100,000 shares @ .01 as an “all or none limit” order. By doing this they are telling the market that they wish to be filled on their entire position at .01 or not to be filled at all. For some reason we have seen market makers ignore these sort of orders on many occasions especially when a stock is on the move. We suggest against it but you will ultimately make the decision. Do Not Chase (ONE OF THE MOST IMPORTANT): Many people want to buy a stock so badly that they end up chasing the stock as it goes up. When they finally fill their order, they may have purchased it too high as traders who bought shares earlier begin to take profit, effectively lowering the stock price and making you a bag holder. Remember, 90% of the time, a stock will always retrace/dip back to an attractive level for you to grab shares. Stock Gaps: If a stock gaps up too high in pre-market, do Not Chase It. A big gap is typically 20-50% or more pre- market or within the first 5-10 minutes of the market opening. Most stocks that gap up will come down again during the day depending on what created the catalyst. Buying is always the catalyst but every once in a while there is earthshattering news on some of these small caps that makes pullbacks unlikely in the short term. Most of the time, when a stock gaps up the market makers will attempt to push it lower starting at this time to try to get investors to panic and sell shares back to them so they can make a profit on any shares they are short from filling orders on the gap. If you like the stock and it gaps up you can usually pick up cheaper shares when and if the market settles back. Sell Into Strength Not Weakness: Once you have taken a position in a stock you need to decide the price you would like to sell your shares. Most would recommend that you put a GTC sell order at that price. Unfortunately as traders have learned to utilize level 2, its best not to do submit GTC sell orders due to the possibility that your order will be represented by a market maker and it will seem as if there is resistance at that level which may compel sellers to get out of their position at a price lower than your price. We suggest that you watch the stock closely and once it hits your price target you can submit your order to sell. It’s important to understand that it’s always best to liquidate the stock into strength and preferably in smaller increments if you have a big position. There you have it!! These are ALL my biased, amateur and unlicensed opinions, should YOU choose freely, knowingly and intelligently to Play ANY of my featured play's!! (Please READ my statement below as well, it will help you understand how I benefit from this newsletter) Also always remember that every single alert I send is very volatile and risky. Any one of them could turn into a big loser. In my personal opinion, no matter how much potential any company has, 99% of the time all that matters is HOW THE STOCK TRADES. If a stock doesn’t trade well, nothing else matters. Don’t believe the hype. Be sure to use a tight stop, book profits quickly on these volatile trades, never let any one trade move too far against you, watch out for gaps, make sure the stock is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. It’s always safest to book profits quickly, even on alerts with long-term potential. (Amateur biased unlicensed opinions) I would like to also explain how my Newsletter Makes MONEY!! I DON’T FRONTLOAD, BUY, RECEIVE any SHARES of a Company I Profile!! I NEVER OWN ANY POSITION IN A COMPANY I ALERT/PROFILE!! It would be UNFAIR, WRONG and ILLEGAL for me to have a position in ANY Company I ever Profile on my Newsletter! I am what is known as a STOCK PROMOTER!! I just wanted to address this issue for some people who might think I trade the companies I profile on my Newsletter or I own a position before or during the time I profile them!!! The honest truth is I DO NOT!!….. I do get CASH compensation to profile companies most of the times I talk about them in my Newsletter, this is HOW I MAKE MONEY and pretty much how 99% of ALL the other Newsletters out there make money…… Most of you have signed up to my Newsletter because of an advertisement you saw, well it costs money to run those advertisements…. I ALWAYS Disclose how much and who paid me in my Disclaimer at the end of each e-mail!!! Here is some information directly from the SEC Website: [( Tips for Checking Out Newsletters “Find out whether the newsletter received payment to “tout” or recommend the stock and, if so, what it received and from whom. Because the U.S. Constitution’s First Amendment protects freedom of speech, the SEC cannot simply prohibit newsletters from recommending or touting particular stocks. But when newsletters receive payment for touting, the securities laws require them to disclose specifically who paid them, the amount, and the type of payment (cash, stock, or some other thing of value). Read carefully what the newsletter says about payments it receives. Be suspicious of newsletters that do not specifically disclose these items: who paid them, the amount, and the type of payment. The following examples raise red flags because they do not contain specific information: “From time to time, XYZ Newsletter may receive compensation from companies we write about.” “From time to time, XYZ Newsletter or its officers, directors, or staff may hold stock in some of the companies we write about.” “XYZ Newsletter receives fees from the companies we write about in our newsletter.” Think twice about newsletters that bury their disclosures or put them in tiny, hard-to-read typeface. Legitimate online newsletters that have been paid to tout stocks will clearly and specifically tell investors who paid them, the amount, and the type of payment. Look for their disclosure statements in articles about particular companies or in a list or chart on their websites.” I hope this answers a lot of your questions and also gives you a better perspective to my play’s the Next Time you see one!! Don’t forget to tell everyone you know about PTE.la and help my Newsletter Grow!! Remember to trade smart, research your options, and use due diligence! Sincerely, PTE.la © 2016 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as arecommendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit [](. PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has been compensated up to Twenty-Five Thousand Dollars Cash via bank wire transfer by a third party (ALG Financial) for a 1 day marketing program regarding VBIO. Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website [www.sec.gov]( and the Financial Industry Regulatory Authority (“FINRA”) website at [www.finra.org](. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. [Disclaimer]( If you no longer wish to receive our emails, click the link below: [Unsubscribe]( Pro Trader Elite 146 Ferry St Newark, New Jersey 07105 United States